These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 26166416)

  • 1. Preparation and functional characterization of human vascular endothelial growth factor-melittin fusion protein with analysis of the antitumor activity in vitro and in vivo.
    Wang D; Hu L; Su M; Wang J; Xu T
    Int J Oncol; 2015 Sep; 47(3):1160-8. PubMed ID: 26166416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of melittin on growth and angiogenesis of human hepatocellular carcinoma BEL-7402 cell xenografts in nude mice].
    Song CC; Lu X; Cheng BB; DU J; Li B; Ling CQ
    Ai Zheng; 2007 Dec; 26(12):1315-22. PubMed ID: 18076793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy.
    Liu M; Wang H; Liu L; Wang B; Sun G
    J Transl Med; 2016 Jun; 14(1):155. PubMed ID: 27246873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
    Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
    Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Jiedu Xiaozheng Yin, a Chinese herbal formula, inhibits tumor angiogenesis via downregulation of VEGF-A and VEGFR-2 expression in vivo and in vitro.
    Cao Z; Lin W; Huang Z; Chen X; Zhao J; Zheng L; Ye H; Liu Z; Liao L; Du J
    Oncol Rep; 2013 Mar; 29(3):1080-6. PubMed ID: 23254951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and anticancer activity analysis of recombinant human uPA1‑43-melittin.
    Su M; Chang W; Cui M; Lin Y; Wu S; Xu T
    Int J Oncol; 2015 Feb; 46(2):619-26. PubMed ID: 25394558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triple-controlled oncolytic adenovirus expressing melittin to exert inhibitory efficacy on hepatocellular carcinoma.
    Qian CY; Wang KL; Fang FF; Gu W; Huang F; Wang FZ; Li B; Wang LN
    Int J Clin Exp Pathol; 2015; 8(9):10403-11. PubMed ID: 26617748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sprengerinin C exerts anti-tumorigenic effects in hepatocellular carcinoma via inhibition of proliferation and angiogenesis and induction of apoptosis.
    Zeng KW; Li N; Dong X; Ma ZZ; Jiang Y; Jin HW; Tu PF
    Eur J Pharmacol; 2013 Aug; 714(1-3):261-73. PubMed ID: 23684542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melittin exerts an antitumor effect on non‑small cell lung cancer cells.
    Zhang SF; Chen Z
    Mol Med Rep; 2017 Sep; 16(3):3581-3586. PubMed ID: 28713976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The anti-cancer potency and mechanism of a novel tumor-activated fused toxin, DLM.
    Sun D; Sun M; Zhu W; Wang Z; Li Y; Ma J
    Toxins (Basel); 2015 Feb; 7(2):423-38. PubMed ID: 25658509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction and expression of sTRAIL-melittin combining enhanced anticancer activity with antibacterial activity in Escherichia coli.
    Liu H; Han Y; Fu H; Liu M; Wu J; Chen X; Zhang S; Chen Y
    Appl Microbiol Biotechnol; 2013 Apr; 97(7):2877-84. PubMed ID: 23149754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melittin suppresses VEGF-A-induced tumor growth by blocking VEGFR-2 and the COX-2-mediated MAPK signaling pathway.
    Huh JE; Kang JW; Nam D; Baek YH; Choi DY; Park DS; Lee JD
    J Nat Prod; 2012 Nov; 75(11):1922-9. PubMed ID: 23110475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
    Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
    Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
    Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
    Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FP3: a novel VEGF blocker with anti-angiogenic and anti-tumor effects.
    Gao W; Jin K; Lan H; Han N; Cao F; Teng L
    Hepatogastroenterology; 2012; 59(120):2543-7. PubMed ID: 22534543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
    Wu Y; Zhong Z; Huber J; Bassi R; Finnerty B; Corcoran E; Li H; Navarro E; Balderes P; Jimenez X; Koo H; Mangalampalli VR; Ludwig DL; Tonra JR; Hicklin DJ
    Clin Cancer Res; 2006 Nov; 12(21):6573-84. PubMed ID: 17085673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation and Characterization of Gelonin-Melittin Fusion Biotoxin for Synergistically Enhanced Anti-Tumor Activity.
    Shin MC; Min KA; Cheong H; Moon C; Huang Y; He H; Yang VC
    Pharm Res; 2016 Sep; 33(9):2218-2228. PubMed ID: 27251414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Photochemical internalization augments tumor vascular cytotoxicity and specificity of VEGF(121)/rGel fusion toxin.
    Weyergang A; Cheung LH; Rosenblum MG; Mohamedali KA; Peng Q; Waltenberger J; Berg K
    J Control Release; 2014 Apr; 180():1-9. PubMed ID: 24531010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor.
    Wang D; Tang F; Wang S; Jiang Z; Zhang L
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):173-83. PubMed ID: 21638122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.